bluuebunny/crossref_metadata_2025_split huggingface dataset:
Plasma Exchange in Radiculopolyneuropathies
Authors: Marconi G. , Bobbi S. , Pizzi A. , Sbrilli C. , Taiuti R. , Ronchi O. , Avanzi G. , Lombardo R. , Franco C. , Biani D. 
Published: April 2018

The AA. report the results obtained with Plasma Exchange (P.E.) therapy on 24 cases of polyradiculoneuritis; eleven patients had typical Guillain-Barré Syndrome (G.B.S.) ten suffered from a chronic progressive form and three were affected by a relapsing form. The acute patients were selected according to criteria established by the NNCDS Committee (1978) while guidelines laid down by Pineas & Load (1978) were followed in choosing chronic cases. Patients with G.B.S. had four sessions of P.E. at intervals of one or two days while those with chronic forms of polyradiculoneuritis had a total of 6 sessions spaced one to three days apart. P.E. produced no apparent change in chronic progressive patients but two out of three cases with the chronic relapsing form showed rapid and steady improvement resulting in complete cure within a few months. Nine of the eleven G.B.S. patients showed after only one or two sessions a clear and rapid improvement which led to a complete cure within a matter of weeks. The remaining 2 cases showed only partial improvement at first and remained stationary thereafter. The findings confirm the usefulness of P.E. in acute and chronic relapsing radiculopolyneuritis. However, potential side effects and the procedure's high cost suggest that its use should be limited to carefully selected cases, and in particular to those involving respiratory disorders.
Serum Sodium Concentration and Body Fluid Distribution during Interdialysis: Importance of Sodium to Fluid Intake Ratio in Hemodialysis Patients
Authors: Kimura G. , Gotch F.A. 
Published: April 2018

Changes in the serum Na+ concentration and transcellular body fluid distribution during the interdialytic period were simulated as functions of body weight gain assuming that the effective extracellular osmolality consists only of sodium. Our model shows that these changes are mainly determined by the relative ratio between sodium intake and weight gain in this period. If the sodium intake-to-net fluid intake ratio is equal to the postdialytic serum [Na+], neither changes in serum [Na+] nor transcellular fluid shifts occur. When sodium intake is relatively greater than the net water intake, serum [Na+] is increased and transcellular fluid shifts will occur out of the cells. On the other hand, when the net water intake is relatively greater than the sodium intake, serum [Na+] is decreased and fluid is distributed to both the intracellular and extracellular compartments. The combined application of our models for both the intradialytic interval described previously and the interdialytic interval described here is very useful in quantitatively analyzing the overall sodium and water metabolism in dialyzed patients.
Serum Phosphate Concentration with Relation to the Hematocrit Value in Uremic Patients on Chronic Hemodialysis
Authors: Gonella M. , Fanara G. , Buzzigoli G. , Bartolini V. , Mariani G. 
Published: April 2018

The acute effects of hemodialysis on the serum inorganic phosphorus levels (sPi) with relation to the predialysis plasma volume (PV) and the hematocrit (Ht) values were studied in a group of chronic uremic patients on regular hemodialysis. The results obtained confirmed the close direct correlation between predialysis sPi and fall in sPi induced by hemodialysis. Furthermore, the present fall in sPi induced by hemodialysis was found to be directly correlated to the PV values, and inversely to the HT values. An equation was derived from these data to predict in the individual patients the postdialysis sPi levels, utilizing both the predialysis sPi and the Ht values; this equation showed a better predictive capability than similar expression based on the use of the predialysis sPi value alone.
Comparison of Four Different Short Dialysis Techniques
Authors: Ronco C. , Fabris A. , Chiaramonte S. , De Dominicis E. , Feriani M. , Brendolan A. , Bragantini L. , Milan M. , Dell'Aquila R. , La Greca G. 
Published: April 2018

The goal of shortening dialysis treatment time has stimulated the development of new, highly efficient dialytic strategies. In this study the Authors compared four different short dialysis treatments in terms of efficiency, clinical tolerance, technological investment and costs: 1) Rapid bicarbonate dialysis with 1.5 sq.m. cuprophane membrane; 2) High flux biofiltration with 1.2 sq.m. AN69S hollow fiber membrane; 3) Hemodiafiltration with 1.2-1.9. sq.m. polysulphonic hollow fiber hemodiafilters, and 4) High flux hemodiafiltration with two serial hemodiafilters with AN69s membrane (total 2.4 sq.m.). Hydraulic properties and solute clearances at different blood flows (300-500 ml/min) were tested for each technique. Once the optimal operative level was established three patients were treated with each technique for at least six months. Since BUN clearance averaged 310 ml/min, the treatment duration varied from 120 to 180 min/session with KT/V always higher than 1. The average protein catabolic rate was 0.9 g/kg/24h. Clinical tolerance was generally good, slightly better in treatments with a high convective component. Despite the greater efficiency of treatment No. 4, the technological requirements and costs are such that the others are currently more feasible and acceptable in clinical routine. The study demonstrates that reduction of dialysis treatment time is possible in all centres in a selected population with adequate blood access. Treatment No. 1 can even be performed with standard equipment and cuprophan membranes, while bicarbonate in the dialysate is mandatory. The real limit to shortening treatment time seems to be related to the maximal rate of ultrafiltration achievable in the patient during dialysis.
A Portable Pneumatic Driving Unit for a Left Ventricular Assist Device
Authors: Kabei N. , Shimemura E. , Sakurai Y. , Tsuchiya K. 
Published: April 2018

The authors developed a portable air driving unit for an artificial heart. As the portable energy source of the driver, a commercially available Ni-Cd battery was used. A linear compressor was selected as a portable size compressor. To reduce the number of parts to be assembled, a new type of pneumatic system was employed. In this system, the pressure level was regulated by varying the output flow rate of the compressor instead of using a pressure regulator and large air reservoirs. A one-board microcomputer and pressure sensors were used to control the pressure level. The total weight of the unit is 9.5 Kg. After assembling the components into the portable unit, a blood pump was connected to examine the output characteristics of the system. It was confirmed that the unit could drive the blood pump continuously for more than 2 hours under the following conditions: output flow rate of the blood pump = 5 L/min and output pressure — 100 mmHg.
Pharmacokinetics of Paracetamol, Diclofenac and Vidarabine during Plasma Exchange
Authors: Fauvelle F. , Leon A. , Niakate M.T. , Petitjean O. , Guillevin L 
Published: April 2018

In order to establish guidelines for prescribing drugs in patients treated with plasma exchange (PE), we studied the pharmacokinetics of paracetamol (5 patients), diclofenac (4 patients) and vidarabine (3 patients) during one or several PE. Results were compared with those obtained without PE. Diclofenac and paracetamol were choosen because they presented different volume distribution and protein binding characteristics. Vidarabine was studied because we use it for the treatment of patients with polyarteritis nodosa related to hepatitis B virus. Diclofenac (100 mg) and paracetamol (1000 mg) were given 1 hour before PE. Samples were obtained 60 and 30 min before PE, every 15 min during PE and hourly for 2 hours after the end of PE. Vidarabine was given in continuous infusion, 15 mg/kg/d during the first week of treatment and 7.5 mg/kg/d during subsequent weeks. Samples were obtained before PE, 3 times during PE and every 30 min for 4 hours after the end of PE. Paracetamol, diclofenac, vidarabine and hypoxanthine arabinoside were assayed by high performance liquid chromatography. During each PE 60 ml/kg were removed and replaced by albumin. We found that 17% of diclofenac, 4.3% of paracetamol and 4.9% of vidarabine were removed during each session. Plasmapheresis clearance was 51% of plasma clearance for diclofenac, 15% for paracetamol and 10% for vidarabine. Drugs which are mainly removed during PE are those which are bound to proteins with a small distribution volume. Those drugs, such as diclofenac, must be administered after the end of each PE session. Drugs which present a large distribution volume and low protein binding can be given before the session. Vidarabine can be administered during PE without loss of effectiveness due to drug removal.
Plasma Collection Using Nafamostat Mesilate and Dipyridamole as an Anticoagulant
Authors: Hiraishi M. , Yamazaki Z. , Ichikawa K. , Kanai F. , Idezuki Y. , Onishi K. , Takahama T. , Inoue N. 
Published: April 2018

Nafamostat mesilate (FUT-175) is a strong protease inhibitor and is used as an anticoagulant in extracorporeal circulation. In the present study, we administered FUT and dipyridamole as anticoagulants during donor plasmapheresis, and the additional effect of dipyridamole was examined. In dogs weighing about 15 Kg, donor plasmapheresis was performed using a cellulose triacetate membrane plasmaseparator (PEX-15, Nipro), and 300 ml of filtrated plasma was obtained within 30 minutes. These dogs were divided into two groups, 50 mg/h of FUT alone was infused (group A, n=10), and the same dose of FUT and 25 mg/h of dipyridamole were infused (group B, n=5) during plasmapheresis. Changes of the coagulation system, blood cell counts and complement system were investigated. In clinical cases, an artificial liver support therapy using FUT as an anticoagulant was performed on 8 patients with acute liver failure, and blood compatibility was examined. In dogs, RBC counts and hematocrits were almost stable, but WBC counts were decreased to about 70% of the previous value. Platelets counts were about 60% and 80% of the previous value, in group A and group B, respectively, at the end of the plasmapheresis (P<0.01). Clotting factor VIII was diminished to about 20% and 35% of the previous value in group A and B, respectively. In clinical cases, all patients received the plasma exchange combined with hemodialysis using FUT as an anticoagulant, and no distinct side effect was observed during plasma exchange.
Development of Smaller Artificial Ventricles and Valves Made by Vacuum Forming
Authors: Pantalos G.M. , Chaing B.Y. , Bishop D.N. , Perkins P.A. , Yu LS. , Jansen J. , Socha P.A. , Marks J.D. , Riebman J.B. , Burns G.L , Kolff W.J. , Hansen G. , Wildevuur W. , Wurzel D. , Brownstein L. , Kolff J. 
Published: April 2018

Implantable prosthetic ventricles and trileaflet valves made by vacuum forming have been developed and implant tested. All components are made from Pellethane®. Recognizing the need for smaller as well as larger ventricles, designs with effective stroke volumes of 50, 85, 100 and 130 cc have been tested with several valve types. The pneumatically driven Utah ventricular assist device (UVAD) can be used as a total artificial heart (TAH) or ventricular assist device (VAD) by using the appropriate inflow and outflow adapters. In vitro durability testing has demonstrated ventricular lifetime beyond two years and valve lifetime to nearly one and one half years. The polymer valves have lower regurgitation than mechanical valves. Animal implantation experience includes 21 TAH implants and 16 left ventricular assist device (LVAD) implantations. TAH survival ranges from 2 to 210 days. LVAD animals have lived up to 116 days before elective termination. The animal were healthy and grew normally. The devices exhibit a “Starling's Law” response. One TAH animal survived 72 days before successful explantation followed by transplantation. At autopsy, this animal had no renal infarcts. Hematology data has demonstrated the existence of little or no intravascular hemolysis (PF Hb < 5 mg%). The “Philadelphia” version of the UVAD vacuum formed ventricles are small enough to be implanted without thrombus provoking connectors. Eight animals have received this TAH and survived up to 120 days. Vacuum forming offers a rapid and inexpensive way to produce reliable and effective total artificial hearts and valves for widespread, temporary clinical application in any size adult human.
Implant of Autologous Mesothelial Cells in Animals and a Peritoneal Dialysis Patient
Authors: Di Paolo N. , Sacchi G. , Vanni L. , Corazzi S. , Pallini V. , Rossi P. , Gaggiotti E. , Buoncristiani U. 
Published: April 2018

Success in culturing human and animal peritoneal mesothelial cells for the purpose of study, led us to determine whether these cells could be autoimplanted in animals and man during peritoneal dialysis in cases of acute and extensive loss of mesothelial surface area. Using an original biopsy technique, we were able to cultivate and characterize from the structural and caryological point of view, human and rabbit peritoneal mesothelial cells. Staphylococcal peritonitis was provoked in 12 rabbits with in-dwelling peritoneal catheters and after 4 days of antibiotic therapy, 6 of them were autoimplanted with cultured mesothelial cells. In the animals sacrificed on the third and sixth days, direct morphological observation and autoradiographic techniques showed that the transplanted cells had taken and revealed a different picture from that in the non-transplanted rabbits. In a 56 year old female diabetic patient, upon insertion of the first peritoneal catheter, a specimen of mesothelial cells was cultured and then frozen. Seven months later after an episode of peritonitis from Candida which dictated removal of the peritoneal catheter, since there was a sufficient number of cultured mesothelial cells and the patient consented, the implant was performed. Peritoneal biopsy by laparoscopy three and six days later showed that the cells had taken. The purpose of the study was merely to show that autoimplant of mesothelium in man and animals is possible.
Long-Term Safety and Efficacy of Programmable Implantable Insulin Delivery Systems
Authors: Olsen C.L. , Liu G. , Iravani M. , Nguyen S. , Khourdadjian K. , Turner D.S. , Waxman K. , Selam J-L. , Charles M.A. 
Published: April 2018

Objectives Since only short-term studies of continuous intraperitoneal insulin infusion (CIPII) therapy using implantable programmable insulin delivery systems have been performed to show this method of diabetes therapy to be safe and efficacious, we have performed long-term studies to assess its safety and efficacy. Research design and methods For 78 patient-years of follow-up, we have longitudinally studied the incidence of diabetic ketoacidosis and severe hypoglycemia in 25 type 1 diabetic patients treated with CIPII. We also compared, cross-sectionally, the long-term safety and efficacy of CIPII to intensive subcutaneous insulin therapy using intermittent injections or continuous subcutaneous insulin infusion. Finally, we examined the relationship between glycated hemoglobin levels and the standard deviation of daily blood glucose excursion. Results Cross-sectional analysis revealed similar degrees of metabolic control accompanied by significantly decreased rates of both ketoacidosis (0.013 events/patient/year) and severe hypoglycemia (0.05 events/patient/year) during CIPII compared to intermittent injections and continuous subcutaneous insulin infusion therapy. A four-fold decrease in the rate of severe hypoglycemia was observed during longitudinal comparison of pre- and post-implantation complication rates. A relationship was also shown between decreased levels of mean glycated hemoglobin and the standard deviation of blood glucose excursions during CIPII therapy. Conclusions Our data demonstrate that long-term therapy with CIPII is as effective as other methods in achieving near-normal levels of glycated hemoglobin, which in CIPII is associated with a decreased standard deviation of blood glucose excursions. Further, CIPII using implantable programmable insulin delivery systems is the safest method described for intensive insulin therapy in home blood glucose monitoring type 1 diabetic patients.
Peripheral Blood Stem Cell Transplantation: Critical Review
Authors: Hénon P.R. 
Published: April 2018

Autologous blood stem cell transplantations have been increasingly performed worldwide for almost ten years in place of autologous bone marrow transplantation and even of allogenic bone marrow transplantation. Several crucial issues were the subjects of impassioned controversies. Some of them are now satisfactorily answered while others still remain unresolved. First, it is now possible to conclude today that peripheral blood stem cells (PBSC) are undoubtedly capable of restoring short term hematopoiesis when reinfused after myeloablative therapy as well and even more rapidly than bone marrow stem cells, provided that they have been previously collected in sufficient amounts. On the opposite, it is still impossible to firmly prove that their very immature CD34+ cell subset, although in vitro functionally and phenotypically almost identical to their marrow counterpart, is actually responsible for sustained long term hematopoietic recovery, even if it is likely that these cells play a key role. Most of the time, using chemotherapy alone or a combination of chemotherapy and cytokine(s), mobilizing regimens allow collection of appropriate yields of PBSC with only a small number of apheresis cycles, provided that a sufficient number of residual stem cells remains to be stimulated, when, on the contrary, collection in steady-state is time-consuming and does not provide further accelerated post transplant hematopoietic recovery. It was initially hypothesized that PBSC could have a lower likelihood of tumoral contamination compared with bone marrow. In fact, biological as well as clinical data are discordant and probably depend largely on the type of disease, its evolutive history and its way of dissemination. Furthermore, the respective impact on the development of further relapse of graft contamination and of residual tumor cells into patient remains to be determined. Finally, although it has often been claimed that the cost of mobilization, collection and cryopreservation of PBSC would be much higher than the cost of bone marrow harvesting, it is now possible to assert that the whole ABSCT procedure, including this preliminary phase, as well as the post-transplant period, allows an indisputable saving compared with ABMT. These advantages are already sufficient reasons “per se” to propose ABSCT in place of ABMT or alloBMT in many indications even if their clinical benefit, in terms of disease-outcome, remains to be prospectively explored.
Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (PSCT) in Patients with Malignant Lymphomas and Solid Tumors
Authors: Richel D.J. , Van Der Wall E. , Slaper J. , Van Der Schoot E. , Rodenhuis S. 
Published: April 2018

Peripheral blood stem cells can reconstitute bone marrow function after high-dose chemo-Zradiotherapy. We describe 44 patients related with a three-day course of chemotherapy, for hematopoietic stem cell mobilization, consisting of cyclophosphamide or ifosfamide and etoposide (malignant lymphoma and germ cell tumor) or a one-day course of 5-fluorouracil, epirubi-cin and cyclophosphamide (breast cancer), followed by the administration of recombinant human granulocyte colony-stimulating factor (G-CSF). Maximum numbers peripheral blood stem cells (PBSC) were recruited on day 9-10 of the G-CSF administration. The total number of PBSC cells harvested with median 3.6 leukaphereses was 46 x 104/kg (7.5-136) CFU-GM or 8 x 106/kg (0.7-25.0)CD34+ cells for patients with solid tumors and 26 (4.5-258) CFU-GM's or 6.1 (1-0-39.2) CD34+ cells for patients with malignant lymphomas. Thirty-five patients with malignant lymphomas or solid tumours received high-dose chemotherapy followed by bone marrow and PBSC infusion (n=8) or PBSC cell infusion alone (n=27). The recovery of granulocytes, platelets and reticulocytes after peripheral stem cell transplantation (-PSCT) in addition to or instead of bone marrow, was markedly accelerated compared with the infusion of BM alone. The accelerated haemopoietic recovery was associated with a reduction in platelet and red blood cell transfusion, reduction in fever periods and earlier discharge from hospital. PSCT is an important alternative to autologous bone marrow transplantation (ABMT). This transplantation technique may also allows application of multiple-cycle intensive chemotherapy.
Gene Therapy and Apheresis
Authors: Servida P. , Bordignon C. 
Published: April 2018

Gene therapy is becoming a real therapeutic chance in some genetic disorders. The first candidates to this approach are genetic diseases which involve hematopoiesis, because of the facility for the collection and the manipulation of hematopoietic progenitors. Apheresis techniques, which are able to collect a great number of mononuclear cells from peripheral blood, are ideal for obtaining a large number of cells which can be transfected. Future uses of gene therapy techniques could be: the treatment of hematopoietic genetic disorders, procedures of gene marking, and the manipulation of normal hematopoietic cells with the objective of increasing their resistance to myelotoxic drugs.
Experience of Computer-Aided Management of Hemapheresis Unit
Authors: Scarpato N. , Falco C. , Nappi G. , Formisano S. 
Published: April 2018

Several programs are available for blood banks management but none of them is particularly made for hemapheresis. We studied a data base application able to manage any aspect of hemapheresis unit activity. The programming general criteria were: 1) easiness of use even for people without any previous experience in using Personal Computers; 2) maximum saving time in operating; 3) easily modifiable system in reply to problems or new needs; 4) automatic checks in order to have the highest automation together with the smallest error risk; 5) quick view on state of activity and on material consumption; 6) simplification of donor recruitment. After a three year long experience, we describe our program structure in order to give a basis for the development of a standardized management system which is useful for different needs and open to future applications of blood cell separators.
Organization and Technical Problems of LDL-apheresis
Authors: Scarpato N. , Falco C. , Nappi G. , Formisano S. 
Published: April 2018

The Authors consider problems related to technique and organization of LDL-Apher-esis with respect to some particular aspects. They evaluate: a) Technical complexity of procedures both in devices to use and in staff preparation; b) Length of treatment which conditions the other fields of activity; c) Problems in management treatments periodicity; d) Usually high cost of this kind of procedures; e) Problems related to vascular accesses; f) Problems related to pediatric patients, both for their low weight and vascular accesses; g) Management of cardiovascular complications; h) Difficulties in evaluation of regression of vascular lesions. Finally, it is particularly difficult the management of psychological aspects related to somatic symptoms of the disease and to the acceptance of treatment.